What is Noble Financial’s Estimate for ELDN FY2026 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Free Report) – Equities researchers at Noble Financial upped their FY2026 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a report issued on Monday, November 16th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings of ($0.58) per share for the year, up from their previous forecast of ($0.74). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.58) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q4 2026 earnings at ($0.20) EPS.

A number of other equities analysts have also issued reports on the stock. Weiss Ratings raised shares of Eledon Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, November 9th. Wall Street Zen raised shares of Eledon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, November 14th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $12.00.

Check Out Our Latest Research Report on ELDN

Eledon Pharmaceuticals Trading Down 6.4%

Shares of Eledon Pharmaceuticals stock opened at $1.90 on Wednesday. The company’s fifty day simple moving average is $2.49 and its 200-day simple moving average is $3.11. The company has a market cap of $160.47 million, a price-to-earnings ratio of -2.60 and a beta of 0.95. Eledon Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $4.49.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

Institutional Trading of Eledon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC acquired a new position in Eledon Pharmaceuticals during the second quarter worth $2,552,000. Bank of America Corp DE grew its holdings in shares of Eledon Pharmaceuticals by 1,346.9% in the 1st quarter. Bank of America Corp DE now owns 869,544 shares of the company’s stock worth $2,678,000 after purchasing an additional 809,446 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter worth about $20,188,000. AWM Investment Company Inc. bought a new stake in Eledon Pharmaceuticals during the second quarter worth about $4,334,000. Finally, Triumph Capital Management acquired a new stake in shares of Eledon Pharmaceuticals during the second quarter worth approximately $1,196,000. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious diseases involving the immune system. The company’s research focuses on modulating immune responses to help address conditions such as organ transplant rejection and amyotrophic lateral sclerosis (ALS). Its lead investigational product, tegoprubart, is an antibody that targets CD40 ligand, a protein involved in immune-system activation. Eledon is studying tegoprubart as a potential treatment to reduce rejection following organ transplantation and in research involving ALS.

Read More

Earnings History and Estimates for Eledon Pharmaceuticals (NASDAQ:ELDN)

Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.